Want to see FTRE full AI Analyst Report?
FTRE Stock Chart & Stats
$18.86
$0.07(0.36%)
At close: 4:00 PM EDT
$18.86
$0.07(0.36%)
Day’s Range― - ―
52-Week Range$8.31 - $21.39
Previous CloseN/A
Volume105.54K
Average Volume (3M)1.48M
Market Cap
$1.68B
Enterprise Value$2.60K
Total Cash (Recent Filing)$168.60M
Total Debt (Recent Filing)$1.12B
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Nov 05, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding95,100,000
10 Day Avg. Volume995,487
30 Day Avg. Volume1,481,739
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.79
Price to Sales (P/S)0.58
P/FCF Ratio17.82
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$22.00Price Target Upside16.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)0.84
Revenue Forecast (FY)$2.66B
Bulls Say, Bears Say
Bulls Say
Commercial Momentum And BacklogSustained bookings above recognized revenue and a large backlog support future revenue visibility. Biotech-weighted awards and CPS demand provide a foundation for continued study conversion over the next several quarters.
Cash Generation And LiquidityPositive operating and free cash flow provide internal funding for operations, debt reduction, and investment despite accounting losses. More than $0.5B of liquidity also improves resilience while Fortrea works through execution and margin challenges.
Cost Efficiency And GuidanceCost reductions, lower direct costs, and reduced SG&A can support durable margin improvement if maintained. The raised EBITDA outlook indicates management expects these efficiency gains and commercial execution to translate into stronger operating performance.
Bears Say
Persistent Losses And Margin PressureContinuing GAAP losses and materially compressed gross margins weaken retained capital and limit flexibility to absorb operational setbacks. Revenue stabilization alone may not restore profitability unless pass-through, FSP, and delivery economics improve.
Elevated LeverageDeleveraging is a positive step, but elevated leverage and reduced equity leave Fortrea more exposed to earnings volatility and refinancing needs. Continued cash generation is required to preserve liquidity and sustain balance-sheet improvement.
Customer Concentration RiskA concentrated client base makes revenue and capacity utilization vulnerable to the loss, repricing, or delay of a few large programs. This can create lasting volatility in bookings conversion, margins, and cash collection even with a strong backlog.
Fortrea Holdings Inc. News
FTRE FAQ
What was Fortrea Holdings Inc.’s price range in the past 12 months?
Fortrea Holdings Inc. lowest stock price was $8.30 and its highest was $21.39 in the past 12 months.
What is Fortrea Holdings Inc.’s market cap?
Fortrea Holdings Inc.’s market cap is $1.68B.
When is Fortrea Holdings Inc.’s upcoming earnings report date?
Fortrea Holdings Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 60 days.
How were Fortrea Holdings Inc.’s earnings last quarter?
Fortrea Holdings Inc. released its earnings results on Jul 29, 2026. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05.
Is Fortrea Holdings Inc. overvalued?
According to Wall Street analysts Fortrea Holdings Inc.’s price is currently Undervalued.
Does Fortrea Holdings Inc. pay dividends?
Fortrea Holdings Inc. does not currently pay dividends.
What is Fortrea Holdings Inc.’s EPS estimate?
Fortrea Holdings Inc.’s EPS estimate is 0.21.
How many shares outstanding does Fortrea Holdings Inc. have?
Fortrea Holdings Inc. has 95,100,000 shares outstanding.
What happened to Fortrea Holdings Inc.’s price movement after its last earnings report?
Fortrea Holdings Inc. reported an EPS of $0.23 in its last earnings report, beating expectations of $0.18. Following the earnings report the stock price went down -1.449%.
Which hedge fund is a major shareholder of Fortrea Holdings Inc.?
Currently, no hedge funds are holding shares in FTRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fortrea Holdings Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (16.65% Upside)
$22.00 (16.65% Upside)
Blogger Sentiment
Bullish
FTRE Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $253.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.9%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
68.41%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.24%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fortrea Holdings Inc.
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's operations are divided into two main segments: Clinical Services and Enabling Services. Its Clinical Services division offers support across the entire spectrum of clinical pharmacology and development. The Enabling Services segment, conversely, delivers patient access programs and cutting-edge clinical trial technology solutions, aiming to simplify complex randomization processes and optimize the supply of trial medications for its customers. Fortrea presents a range of engagement options, such as full-service provision, functional service provider (FSP) models, and hybrid structures. Additionally, its portfolio includes managing clinical trials from Phase I through IV, offering distinctive technology-powered trial solutions, and providing post-market approval services. The company's client base primarily consists of pharmaceutical, biotechnology, and medical device entities. Fortrea Holdings Inc. was founded in 2023 and has its headquarters in Durham, North Carolina.
FTRE Company Deck
FTRE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted substantial commercial momentum (bookings up, net new business +19% H1), improved profitability metrics (adjusted EBITDA growth, cost savings, SG&A reduction), stronger cash generation and an upgraded full-year guidance, alongside early operational wins from FIT/AI and CPS strength. Key risks discussed include a modest YoY revenue decline driven by pass-through/FSP dynamics, elevated customer concentration, a CFO transition related to a restrictive covenant matter, and the early-stage nature of AI benefits. On balance, the positive operational, commercial and financial traction and the guidance raise outweigh the listed challenges.View all FTRE earnings summariesFTRE Stock 12 Month Forecast
Average Price Target
$22.00
▲(16.65% Upside)
Technical Analysis
Maravai Lifesciences Holdings
―
AbCellera Biologics
―
Recursion Pharmaceuticals
―
MBX Biosciences, Inc.
―
Generate Biomedicines, Inc.
―
Ownership Overview
0.94% Insiders
20.68% Mutual Funds
21.63% Other Institutional Investors
27.59% Public Companies and
Individual Investors